Evidence map›Paper›PMID 34884997›Full record

ArticleCancers2021

Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm.

C Cameron Yin, Naveen Pemmaraju, M James You, Shaoying Li, Jie Xu, Wei Wang, Zhenya Tang, Omar Alswailmi, Kapil N Bhalla, Muzaffar H Qazilbash and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Journal of Cancer · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Multiple Genomic Alterations, Including a NovelInternational journal of molecular sciences · 2023
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

C Cameron YinDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Naveen PemmarajuDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-1670-6513
M James YouDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Shaoying LiDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Jie XuDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Wei WangDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Zhenya TangDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-8079-9945
Omar AlswailmiDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Kapil N BhallaDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Muzaffar H QazilbashDepartment of Stem Cell Transplantation, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Marina KonoplevaDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Joseph D KhouryDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-2621-3584

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive neoplasm derived from plasmacytoid dendritic cells. While advances in understanding the pathophysiology of the disease have been made, integrated systematic analyses of the spectrum of immunophenotypic and molecular alterations in real-world clinical cases remain limited. We performed mutation profiling of 50 BPDCN cases and assessed our findings in the context of disease immunophenotype, cytogenetics, and clinical characteristics. Patients included 42 men and 8 women, with a median age of 68 years (range, 14-84) at diagnosis. Forty-two (84%) patients had at least one mutation, and 23 (46%) patients had ≥3 mutations. The most common mutations involved

Indexed as

blastic plasmacytoid dendritic cell neoplasmDNA methylation pathwayNGSoverall survival

Identifiers

PMID34884997
PMCPMC8656770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.